Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53

Despite a high clinical need for the treatment of colorectal carcinoma (CRC) as the second leading cause of cancer-related deaths, targeted therapies are still limited. The multifunctional enzyme Transglutaminase 2 (TGM2), which harbors transamidation and GTPase activity, has been implicated in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkomes, Patrizia, Lunger, Ilaria, Oppermann, Elsie, Abou-El-Ardat, Khalil, Oellerich, Thomas, Günther, Stefan, Canbulat, Can, Bothur, Sabrina, Schnütgen, Frank, Yu, Weijia, Wingert, Susanne, Haetscher, Nadine, Catapano, Claudia, Dietz, Marina S., Heilemann, Mike, Kvasnicka, Hans-Michael, Holzer, Katharina, Serve, Hubert, Bechstein, Wolf Otto, Rieger, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225513/
https://www.ncbi.nlm.nih.gov/pubmed/34103685
http://dx.doi.org/10.1038/s41388-021-01847-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225513/
https://www.ncbi.nlm.nih.gov/pubmed/34103685
http://dx.doi.org/10.1038/s41388-021-01847-w

Ejemplares similares